Efficacy and safety of Androgen Deprivation Therapy (ADT) combined with modified docetaxel chemotherapy versus ADT combined with standard docetaxel chemotherapy in patients with metastatic castration-resistant prostate cancer: study protocol for a multicentre prospective randomized controlled trial

被引：0
|
作者：
Xiangwei Yang
Hong Chen
Duanya Xu
Xianju Chen
Yamei Li
Jun Tian
Dongwen Wang
Jun Pang
机构：
[1] Sun Yat-sen University,Department of Urology, Kidney and Urology Center, Pelvic Floor Disorders Center, The Seventh Affiliated Hospital
[2] University of Hong Kong,School of Nursing, LKS Faculty of Medicine
[3] National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital,undefined
[4] Chinese Academy of Medical Sciences and Peking Union Medical College,undefined
来源：
BMC Cancer | / 22卷
关键词：
Metastatic castration-resistant prostate cancer; Modified docetaxel chemotherapy; Androgen deprivation therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Efficacy and safety of Androgen Deprivation Therapy (ADT) combined with modified docetaxel chemotherapy versus ADT combined with standard docetaxel chemotherapy in patients with metastatic castration-resistant prostate cancer: study protocol for a multicentre prospective randomized controlled trial
    Yang, Xiangwei
    Chen, Hong
    Xu, Duanya
    Chen, Xianju
    Li, Yamei
    Tian, Jun
    Wang, Dongwen
    Pang, Jun
    BMC CANCER, 2022, 22 (01)
  • [2] Efficacy of Androgen Deprivation Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Docetaxel-Based Chemotherapy
    Min, Kyungchan
    Chung, Jae Wook
    Ha, Yun-Sok
    Lee, Jun Nyung
    Kim, Bum Soo
    Kim, Hyun Tae
    Kim, Tae-Hwan
    Yoo, Eun Sang
    Kwon, Tae Gyun
    Chung, Sung Kwang
    Tanaka, Masatoshi
    Egawa, Shin
    Kimura, Takahiro
    Choi, Seock Hwan
    WORLD JOURNAL OF MENS HEALTH, 2020, 38 (02): : 226 - 235
  • [3] Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis
    Ayer Botrel, Tobias Engel
    Clark, Otovio
    Lima Pompeo, Antonio Carlos
    Horta Bretas, Francisco Flavio
    Sadi, Marcus Vinicius
    Ferreira, Ubirajara
    dos Reis, Rodolfo Borges
    PLOS ONE, 2016, 11 (06):
  • [4] Duration of response to androgen-deprivation therapy (ADT) and efficacy of secondary hormone therapy, docetaxel (D), and cabazitaxel (C) in metastatic castration-resistant prostate cancer (mCRPC).
    Angelergues, Antoine
    Maillet, Denis
    Flechon, Aude
    Ozguroglu, Mustafa
    Mercier, Florence
    Guillot, Aline
    Le Moulec, Sylvestre
    Gravis, Gwenaelle
    Beuzeboc, Philippe
    Massard, Christophe
    Rouge, Thibault De La Motte
    Delanoy, Nicolas
    Elaidi, Reza-Thierry
    Oudard, Stephane
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [5] Enzalutamide plus androgen deprivation therapy (ADT) versus flutamide plus ADT in Japanese men with castration-resistant prostate cancer: AFTERCAB study
    Uemura, Hiroji
    Kobayashi, Kazuki
    Yokomizo, Akira
    Hinotsu, Shiro
    Horie, Shigeo
    Kakehi, Yoshiyuki
    Naito, Seiji
    Nonomura, Norio
    Ogawa, Osamu
    Oya, Mototsugu
    Suzuki, Kazuhiro
    Saito, Atsushi
    Uno, Satoshi
    Akaza, Hideyuki
    BJUI COMPASS, 2022, 3 (01): : 26 - 36
  • [6] Role of Androgen Deprivation Treatment in Patients With Castration-Resistant Prostate Cancer, Receiving Docetaxel-Based Chemotherapy
    Lee, Jae-Lyun
    Kim, Jeong Eun
    Ahn, Jin-Hee
    Lee, Dae-Ho
    Lee, Junghsin
    Kim, Choung-Soo
    Hong, Jun Hyuk
    Hong, Bumsik
    Song, Cheryn
    Ahn, Hanjong
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2011, 34 (02): : 140 - 144
  • [7] Efficacy and safety of enzalutamide (ENZ) vs placebo (PL) in chemotherapy-naive patients (pts) with progressive metastatic castration-resistant prostate cancer (mCRPC) following androgen deprivation therapy (ADT): An Asian multinational study
    Ye, D.
    Ahn, H.
    Pu, Y-S.
    Weiqing, H.
    Xie, L-P.
    Huang, S-P.
    Wu, H-C.
    Ma, L.
    Yamada, S.
    Noda, S.
    Sun, Y.
    ANNALS OF ONCOLOGY, 2016, 27
  • [8] A Multicentric Phase II Randomized Trial of Docetaxel Plus Enzalutamide Versus Docetaxel as First-Line Chemotherapy for Patients With Metastatic Castration-Resistant Prostate Cancer-CHEIRON Study
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (04) : 12 - 12
  • [9] COST-UTILITY ANA LYSIS OF ENZALUTAMIDE FOR PATIENTS WITH CHEMOTHERAPY-NAIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) AFTER FAILURE OF ANDROGEN DEPRIVATION THERAPY (ADT)
    Vicente, C.
    Loblaw, A.
    North, S.
    Kassouf, W.
    Naidoo, S.
    Husein, F.
    Nakhaipour, H. R.
    VALUE IN HEALTH, 2015, 18 (07) : A474 - A474
  • [10] Effectiveness of Deferred Combined Androgen Blockade Therapy Predicts Efficacy in Abiraterone Acetate Treated Metastatic Castration-Resistant Prostate Cancer Patients after Docetaxel
    Li, Jian-Ri
    Chiu, Kun-Yuan
    Wang, Shian-Shiang
    Yang, Cheng-Kuang
    Chen, Chuan-Shu
    Ho, Hao-Chung
    Hung, Chi-Feng
    Cheng, Chen-Li
    Yang, Chi-Rei
    Chen, Cheng-Che
    Wang, Shu-Chi
    Lin, Chia-Yen
    Chang, Chao-Hsiang
    Hsu, Chiann-Yi
    Ou, Yen-Chuan
    FRONTIERS IN PHARMACOLOGY, 2017, 8
12345